Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes

Objectives Hypertension is well established as a major risk factor for cardiovascular disease. Although there is undeniable evidence to support the beneficial effects of antihypertensive therapy on morbidity and mortality, adequate blood pressure management still remains suboptimal. Research into the treatment of hypertension has produced a multitude of drug classes with different efficacy profiles. These agents include β-blockers, diuretics, ACE inhibitors, angiotensin receptor blockers and calcium channel blockers. One of the oldest groups of antihypertensives, the calcium channel blockers are a heterogeneous group of medications. Methods This review paper will focus on amlodipine, a dihydropyridine calcium channel blockers, which has been widely used for 2 decades. Results Amlodipine has good efficacy and safety, in addition to strong evidence from large randomised controlled trials for cardiovascular event reduction. Conclusions Amlodipine should be considered a first-line antihypertensive agent.

[1]  D. DeMets,et al.  Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). , 2013, JACC. Heart failure.

[2]  J. DiNicolantonio.  Hydrochlorothiazide: is it a wise choice? , 2012, Expert opinion on pharmacotherapy.

[3]  R. Fogari,et al.  Effect of Telmisartan and Ramipril on Atrial Fibrillation Recurrence and Severity in Hypertensive Patients With Metabolic Syndrome and Recurrent Symptomatic Paroxysmal and Persistent Atrial Fibrillation , 2012, Journal of cardiovascular pharmacology and therapeutics.

[4]  S. Neldam,et al.  Telmisartan and Amlodipine Single‐Pill Combinations vs Amlodipine Monotherapy for Superior Blood Pressure Lowering and Improved Tolerability in Patients With Uncontrolled Hypertension: Results of the TEAMSTA‐5 Study , 2011, Journal of clinical hypertension.

[5]  M. Hori,et al.  The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function and Atherosclerosis in Japanese Patients with Mild-to-Moderate Hypertension (J-ELAN) study , 2011, Hypertension Research.

[6]  G. Bakris,et al.  Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial , 2010, The Lancet.

[7]  D. Calhoun,et al.  Triple Antihypertensive Therapy With Amlodipine, Valsartan, and Hydrochlorothiazide: A Randomized Clinical Trial , 2009, Hypertension.

[8]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[9]  B. Filho,et al.  An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study. , 2008, Clinical therapeutics.

[10]  R. Hermida,et al.  Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. , 2008, American journal of hypertension.

[11]  M. Melino,et al.  The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. , 2008, Clinical therapeutics.

[12]  R. Fogari,et al.  Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension , 2007, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[13]  D. Triggle.  Calcium channel antagonists: clinical uses--past, present and future. , 2007, Biochemical pharmacology.

[14]  G. Mancia,et al.  Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial , 2006, Journal of hypertension.

[15]  Takahiro Shimizu,et al.  Calcium Channel Blockades Exhibit Anti-Inflammatory and Antioxidative Effects by Augmentation of Endothelial Nitric Oxide Synthase and the Inhibition of Angiotensin Converting Enzyme in the NG-Nitro-L-Arginine Methyl Ester-Induced Hypertensive Rat Aorta: Vasoprotective Effects beyond the Blood Press , 2005, Hypertension Research.

[16]  R. Nagai,et al.  Amlodipine increases nitric oxide production in exhaled air during exercise in patients with essential hypertension. , 2004, American journal of hypertension.

[17]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[18]  S. Chrysant.  The ALLHAT study: results and clinical implications. , 2003, QJM : monthly journal of the Association of Physicians.

[19]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[20]  R. Mason,et al.  Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. , 2002, Atherosclerosis.

[21]  R. Mason.  Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipine. , 2001, The American journal of cardiology.

[22]  R. Hoyt,et al.  Reducing readmissions for congestive heart failure. , 2001, American family physician.

[23]  G. Giacchetti,et al.  Decreased nitric oxide levels and increased calcium content in platelets of hypertensive patients. , 2001, American journal of hypertension.

[24]  Michael E. Miller,et al.  Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events , 2000, Circulation.

[25]  J. Cleland,et al.  Clinical trials update: OPTIME‐CHF, PRAISE‐2, ALL‐HAT , 2000, European journal of heart failure.

[26]  StefanDhein,et al.  Amlodipine Releases Nitric Oxide From Canine Coronary Microvessels: An Unexpected Mechanism of Action of a Calcium Channel–Blocking Agent , 1999 .

[27]  W. Linz,et al.  Interactions among ACE, kinins and NO. , 1999, Cardiovascular research.

[28]  D. DeMets,et al.  Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. , 1998, The American journal of cardiology.

[29]  M. Pahor,et al.  Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.

[30]  O. Eickelberg,et al.  Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection. , 1997, International journal of cardiology.

[31]  P. Erne,et al.  Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P. Vallance,et al.  Forearm blood flow responses to a nitric oxide synthase inhibitor in patients with treated essential hypertension. , 1994, Cardiovascular research.

[33]  S. Taylor.  Usefulness of amlodipine for angina pectoris. , 1994, The American journal of cardiology.

[34]  D. Abernethy.  Pharmacokinetics and pharmacodynamics of amlodipine. , 1992, Cardiology.

[35]  Mehra,et al.  A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. , 1990, Circulation.

[36]  M. Packer,et al.  Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. , 1987, Journal of the American College of Cardiology.

[37]  Jpas Investigators.  Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[38]  W. Elliott.  Prevention of Cardiovascular Events With an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required Versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Tri , 2006 .

[39]  Eric J Topol,et al.  Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. , 2004, JAMA.

[40]  L. Ghiadoni,et al.  Guidelines for antihypertensive treatment: an update after the ALLHAT study. , 2004, Journal of the American Society of Nephrology : JASN.

[41]  M. Mora.  Open Heart , 2003, Annals of Internal Medicine.

[42]  S. Nattel,et al.  Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. , 1991, Circulation.